Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q1 FY23 Earnings Presentation
22 slides from Cohance Lifesciences's earnings presentation, August 2022
Slide 1: Suven Pharma Earnings Presentation Q1 FY23
SUVEN PHARMA Earnings Presentation Q1 FY23
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q1 FY23 3
Slide 4: Operation & Financial Performance Q1 FY23
Operation & Financial Performance Q1 FY23 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDM O Spec Chem Formulations & Other Ser vices 136.36 209.08 210.23 25.54 117.35 153.39 18.42 84.87 11.22 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot
Financial Snapshot Q1FY23 FY22 Growth in Growth in Growth in Revenue EBITDA PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6
Slide 7: Key Ratios
Key Ratios Q1FY23 FY22 EBIT to EBITDA to PAT to Income Income Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7
Slide 8: Financials Q1FY23
Financials Q1FY23 Revenue EBIDTA PAT EPS 4,982 2,245 8.8 2,920 3,497 RUPEES MN RUPEES MN RUPEES MN 2,696 RUPEES 1,656 1,141 4.5 1,204 814 3.2 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 8
Slide 9: Financials Q1FY23
Financials Q1FY23 EBITDA Margin (%) PAT Margin (%) 59% 47% 45% 45% 30% 33% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 9
Slide 10: Financial Table – Q1 FY23
Financial Table – Q1 FY23 Quarter ended Year ended 30-Jun-22 31-Mar-22 30-Jun-21 31-Mar-22 Revenue from operations 3,387.99 3,638.47 2,638.01 13,202.22 Other Income 108.98 1,343.96 57.83 1,877.88 Total Income 3,496.97 4,982.43 2,695.84 15,080.10 EBITDA 1,656.37 2,919.65 1,203.99 7,677.76 EBITDA Marg
Slide 11: Q1FY22 updates
Q1FY22 updates ñPost approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Private Limited (Casper Pharma) situated at GMR Hyderabad SEZ, a company engaged in formulations business for USD 20.50 Mn and has become a wholly owne
Slide 12: Company Background
Company Background PHARMA
Slide 13: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 13
Slide 14: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBITDA and process research & across the entire CDMO Adj. PAT of Rs 3497 Mn, Rs 1656 Mn devel
Slide 15: Brief Overview
Brief Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since
Slide 16: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 16 16
Slide 17: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 17
Slide 18: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 18
Slide 19: Business Drivers
Business Drivers Execution Capabilities Over 92% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 20: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 21: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 22: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q1 FY23 Earnings Presentation on 6ix